Carregant...
A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
BACKGROUND: The discovery of receptor activator of nuclear factor‐ĸB ligand (RANKL) as the final effector in the pathogenesis of osteoporosis has led to a better understanding of bone remodeling. When RANKL binds to its receptor (RANK), osteoclastic differentiation and activation are initiated. Here...
Guardat en:
| Publicat a: | Clin Transl Med |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7967917/ https://ncbi.nlm.nih.gov/pubmed/33784004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.368 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|